Discrimination of Carcinogens by Hepatic Transcript Profiling in Rats Following 28-day Administration
Hiroshi Matsumoto1, Yoshikuni Yakabe1, Koichi Saito2, Kayo Sumida2, Masaru Sekijima3, Koji Nakayama3, Hideki Miyaura1, Fumiyo Saito1, Masanori Otsuka1 and Tomoyuki Shirai4
1Chemical Assessment Center, Chemicals Evaluation and Research Institute, Japan (CerI), 1600, Shimo-Takano, Sugito-machi, Kitakatsushika-gun, Saitama 345-0043, Japan. 2Sumitomo Chemical Co., Ltd., Osaka, Japan. 3Mitsubishi Chemical Safety Institute Ltd., Ibaraki, Japan. 4Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Abstract
This study aimed at discriminating carcinogens on the basis of hepatic transcript profiling in the rats administrated with a variety of carcinogens and non-carcinogens. We conducted 28-day toxicity tests in male F344 rats with 47 carcinogens and 26 non- carcinogens, and then investigated periodically the hepatic gene expression profiles using custom microarrays. By hierarchical cluster analysis based on significantly altered genes, carcinogens were clustered into three major groups (Group 1 to 3). The formation of these groups was not affected by the gene sets used as well as the administration period, indicating that the grouping of carcinogens was universal independent of the conditions of both statistical analysis and toxicity testing. Seventeen carcinogens belonging to Group 1 were composed of mainly rat hepatocarcinogens, most of them being mutagenic ones. Group 2 was formed by three subgroups, which were composed of 23 carcinogens exhibiting distinct properties in terms of genotoxicity and target tissues, namely nonmutagenic hepatocarcinogens, and mutagenic and nonmutagenic carcinogens both of which are targeted to other tissues. Group 3 contained 6 carcinogens including 4 estrogenic substances, implying the group of estrogenic carcinogens. Gene network analyses revealed that the significantly altered genes in Group 1 included Bax, Tnfrsf6, Btg2, Mgmt and Abcb1b, suggesting that p53-mediated signaling pathway involved in early pathologic alterations associated with preceding mutagenic carcinogenesis. Thus, the common transcriptional signatures for each group might reflect the early molecular events of carcinogenesis and hence would enable us to identify the biomarker genes, and then to develop a new assay for carcinogenesis prediction.
Readers of this also read:
- Discrimination of Carcinogens by Hepatic Transcript Profiling in Rats Following 28-day Administration
- In silico Analysis of Human Telomerase Reverse Transcriptase (hTERT ) Gene: Identification of a Distant Homolog of Melanoma Antigen Family Gene (MAGE)
- Decreased Serum Hepatocyte Growth Factor (HGF) in Autistic Children with Severe Gastrointestinal Disease
- Protein Modifications as Potential Biomarkers in Breast Cancer
- DICOM Structured Reporting and Cancer Clinical Trials Results